01 Shift toward Sustainable and Renewable Cellulose Sources Growing environmental concerns and the push toward bio-based materials are encouraging manufacturers to adopt renewable cellulose sources for microcrystalline cellulose production. The increasing focus on sustainable raw materials is supporting the use of wood-based and alternative non-wood cellulose sources, including agricultural residues. For example, the European Commission’s bioeconomy initiatives promote replacing fossil-based resources with sustainable biological materials to support circular production models.
02 Increasing Adoption of Non-Wood-based Feedstocks for MCC Production Manufacturers are increasingly producing microcrystalline cellulose from non-wood biomass such as agricultural residues, bamboo, and cotton linters to diversify raw material sources. This shift supports sustainability initiatives by reducing reliance on wood pulp and utilizing renewable biomass that would otherwise be discarded. The trend is encouraging investment in alternative cellulose extraction technologies and expanding the availability of sustainable MCC across pharmaceutical, food, and personal care applications.
01 The microcrystalline cellulose market forecasts investment activity focused on strengthening pharmaceutical excipient capabilities, innovation infrastructure, and global supply networks. Investments highlight the growing focus on advanced excipient solutions and strengthening competitive positioning in the MCC market. In October 2025, Roquette inaugurated its Pharmaceutical Innovation Center in São Paulo, Brazil. The facility includes laboratories and customer training facilities focused on pharmaceutical formulation development and drug delivery solutions, supporting innovation activities related to pharmaceutical excipients.
01 Supply chain disruptions can significantly impact the microcrystalline cellulose market by affecting the availability and pricing of raw materials such as wood-based and non-wood-based cellulose. Transportation delays, energy cost fluctuations, and shortages of agricultural and forestry-based inputs can disrupt production schedules and increase manufacturing costs. The market is witnessing a U-shaped recovery as supply disruptions, raw material constraints, and production delays initially affected availability before gradual stabilization. Increasing pharmaceutical, nutraceutical, and food industry demand is supporting a steady rebound as manufacturers restore inventories and strengthen supply networks.
01 Increasing Preference for Low-Calorie Food Formulations and Growing Use of MCC in Pharmaceutical Formulations Drive Market Rising health awareness and demand for reduced-calorie food products are increasing the use of microcrystalline cellulose as a fat replacer, bulking agent, and texture enhancer in food applications. This trend is supporting demand from food manufacturers developing low-fat dairy products, bakery items, and dietary foods requiring improved texture with reduced calories. For instance, the World Health Organization recommends limiting free sugar intake to less than 10% of total energy intake, encouraging reformulation efforts toward healthier food products.The increasing production of tablets, capsules, and topical formulations is driving demand for microcrystalline cellulose as a multifunctional pharmaceutical excipient. MCC is widely used as a binder, diluent, disintegrant, and stabilizer in tablets, while also serving as a viscosity modifier and stabilizer in ointments and creams. The expansion of generic drug manufacturing and rising pharmaceutical output are supporting higher consumption of MCC across drug formulations.
01 Stringent Regulatory Approval Requirements and Transportation & Storage Sensitivity Restrain Market Expansion Strict regulatory standards for pharmaceutical and food-grade excipients increase compliance requirements for microcrystalline cellulose manufacturers, requiring extensive quality testing, documentation, and validation processes. These regulatory procedures increase product development timelines and operational costs, which can slow the introduction of new MCC grades and limit adoption among smaller manufacturers. Compliance with global pharmacopeia standards such as USP-NF, EP, and JP remains essential for maintaining market acceptance.Microcrystalline cellulose requires controlled handling, packaging, and storage conditions to maintain its moisture content, functional properties, and product quality during transportation. Improper storage conditions can affect flowability, stability, and performance in pharmaceutical and food formulations, increasing supply chain complexity. These logistics challenges can raise distribution costs and create barriers for manufacturers expanding MCC availability across distant and emerging markets.
01 Development of Specialty MCC Grades and Utilization of Agricultural Waste-based Cellulose Offer Growth Opportunities to Market Players Increasing demand for optimized pharmaceutical formulations is encouraging MCC manufacturers to develop specialty grades with application-specific properties such as improved compressibility, flowability, and moisture control. This creates opportunities for suppliers to support advanced tablet manufacturing processes, including direct compression, dry granulation, and orally disintegrating tablet formulations. For example, IFF offers multiple Avicel® PH microcrystalline cellulose grades, including Avicel PH-102, PH-200, and PH-302, with variations in particle size distribution, density, and moisture content to address different pharmaceutical formulation requirements. This expansion of customized MCC grades supports higher-value excipient adoption across pharmaceutical applications.Growing focus on circular bio-based materials is creating opportunities for converting agricultural residues into cellulose-based ingredients for industrial applications. Research and industrial initiatives are exploring materials such as sugarcane bagasse, rice straw, and bamboo as alternative cellulose sources to reduce dependence on traditional wood pulp. The Food and Agriculture Organization of the United Nations highlights the increasing importance of agricultural residue utilization within sustainable bioeconomy models, with global crop production generating significant amounts of recoverable biomass resources. This creates opportunities for MCC producers to develop alternative raw material supply chains and improve sustainability performance.
01 Need for Continuous Product Innovation and Variability in End-User Formulation Requirements Challenges Market Growth The microcrystalline cellulose market faces challenges in maintaining continuous product innovation as end users increasingly demand advanced grades with improved functionality and application-specific performance. Manufacturers need to invest in research, process optimization, and product development to remain competitive, which can increase operational complexity and slow the introduction of new solutions.Differences in formulation requirements across pharmaceuticals, food, nutraceuticals, and cosmetics create challenges in developing standardized MCC products suitable for multiple applications. The need for customized grades and application-specific properties can increase development efforts, limit scalability, and make it difficult for manufacturers to achieve broad market adoption.
March 2026 DuPont Nutrition & Biosciences (IFF) continued expanding its pharmaceutical excipient solutions portfolio, including cellulose-based excipients used in tablet formulation, binding, and drug delivery applications. The company continued supporting pharmaceutical manufacturers with functional ingredients and formulation technologies.
February 2026 Roquette continued strengthening its pharmaceutical excipients business, including MICROCEL® microcrystalline cellulose solutions used for direct compression, tablet binding, and oral solid dosage formulations. TSource: Roquette official product information.
January 2026 JRS Pharma (J. Rettenmaier & Söhne Group) continued expanding its pharmaceutical excipient portfolio, including VIVAPUR® microcrystalline cellulose products. The company continued developing cellulose-based solutions for pharmaceutical, nutraceutical, and healthcare applications.
November 2025 Asahi Kasei Corporation continued expanding its pharmaceutical excipients portfolio, including Ceolus™ microcrystalline cellulose products. The company continued supporting pharmaceutical companies with high-quality cellulose excipients for tablet manufacturing.